Epidermolysis Bullosa Pruriginosa due to a Glycine Substitution Mutation in the COL7A1-gene

Sigrid M.C. Broekaert1, Evelin Knauss-Scherwitz1, Tilo Biedermann1, Gisela Metzler2, Cristina Has2, Jürgen Kohlhase3, Martin Röcken1 and Martin Schaller4

1Department of Dermatology, University of Tübingen, Liebermeisterstrasse 25, D-72076 Tübingen, 2Department of Dermatology, and 3Institute for Human Genetics and Anthropology, University of Freiburg, Freiburg, Germany. E-mail: Sigrid.Broekaert@med.uni-tuebingen.de

Accepted June 8, 2006.

Sir,

Dystrophic epidermolysis bullosa (DEB) is a clinically heterogeneous genodermatosis with characteristic trauma-induced blistering associated with scarring and nail dystrophy. It results from mutations in COL7A1, the gene encoding type VII collagen. The site and specific nature of the underlying mutation determine the clinical phenotype, which ranges widely from a generalized severe mutilating condition to a relatively mild localized disorder (1). DEB pruriginosa is a distinct clinical subtype of DEB, characterized by prurigo-like or lichenified lesions associated with scarring (2). Scarring is most evident on the limbs, particularly on the shins, with relative sparing of other body areas (2). Disease onset may occur in early childhood, but in some individuals it is delayed until the second or third decade of life (3). Autosomal dominant, autosomal recessive, and sporadic inheritance patterns have been described (2). Due to its possible late onset and its striking similarity to other dermatoses, such as hypertrophic lichen planus, lichen simplex chronicus and cutaneous amyloidosis, this subtype presents a considerable clinical challenge.

CASE REPORT

A 29-year-old Turkish woman presented to our clinic with a 2-year history of pruritic papules on the extensor sides of her feet and lower extremities and similar manifestations on her elbows. Apart from these clinical signs and symptoms and mild nail dystrophy she was in good general health, with no problems with swallowing, bowel functions, nutrition, eyes or teeth. There was no family history of similar skin or nail diseases. There was neither personal history of eczema or atopy nor evidence for other causes of itching, such as internal diseases. Clinical examination revealed multiple lichenified violaceous papules, linear scarring and crusts on the dorsal side of her feet, ankles and distal lower extremities (Fig. 1). On closer inspection, milia were visible between the papules. Her elbows showed similar lesions that were in addition excoriated. Her toe nails showed mild dystrophy, while her mucous membranes were normal. Treatment with unknown topical corticosteroids for several weeks failed to provide relief.

A biopsy from a lichenoid papule showed orthohyperkeratosis, acanthosis and multiple subepidermal splits and no typical criteria for lichen planus. Bullous autoimmune dermatoses, such as epidermolysis bullosa aquisita and pemphigoid were excluded by negative direct and indirect immunofluorescence. Immunohistochemical staining with antibodies against type IV collagen labelled the blister roof. This finding corresponds to blister formation below the lamina densa. Electron microscopy (EM) revealed areas of few or even absent anchoring fibrils (Fig. 2a and b). Confocal laser microscopy supported the diagnosis by verifying the absence or reduction of collagen VII, a main component of the anchoring fibrils (Fig. 2c and d). Mutation analysis of the COL7A1-gene (chromosome 3p21.3) was performed. In the patient’s DNA sample, in exon 110 of COL7A1, the heterozygous mutation c.8137G >C was disclosed. This base substitution leads to a previously reported missense mutation, consisting of an amino acid conversion from glycine to arginine residue at position 2713, designated p.G2713R. This mutation was not present in the DNA of the patient’s son.

Based on these findings we diagnosed DEB pruriginosa. We recommended occlusive tacrolimus therapy, that the patient withdrew from treatment after understanding the genetic origin of her disease.

DISCUSSION

In our patient the diagnosis of DEB pruriginosa was based on both clinical findings and analysis of biopsy specimens by immunofluorescence mapping and EM, confirmed by mutation analysis. Confocal laser microscopy showed abnormal collagen VII staining, which supports the diagnosis of DEB. We employed this technique to demonstrate that, in addition to mutation analysis and immunofluorescence antigenic mapping, it is a useful alternative when EM is not available. This rare localized subtype of DEB was first published by McGrath et al. (2). Clinical features are not usually
Letters to the Editor

present at birth. Typically, as in our patient, disease onset can be delayed until the second or third decade, making clinical diagnosis difficult, especially in cases such as this, with no family history. Clinical findings include lichen planus- or prurigo-like nodules with pruritus as the most prominent and severe symptom. Nail dystrophy is described in the majority of patients, but is not obligatory for diagnosis. Various mutations in the COL7A1-gene have been reported, almost always implicating glycine substitutions in the collagenous triple helical domain of type VII collagen causing disruption of anchoring fibril assembly (3–5). Autosomal dominant, autosomal recessive and sporadic inheritance patterns have been described in this disease (1). In our patient, the heterozygous mutation c.8137G >C, leading to the glycine substitution p.G2713R could be detected. This mutation has been described before in a female patient with dominant DEB pruriginosa aged 29 years at disease onset (3). Interestingly, she inherited the mutation from her father, who had only mild toe nail dystrophy, while a nephew had localized trauma-induced blistering with scarring on his knees (3).

Treatment is very disappointing and mostly symptomatic. However, successful results have been achieved with topical tacrolimus and thalidomide as well as cyclosporine (6–8). Since we were concerned about the peripheral neuropathy associated with thalidomide, we recommended our patient to apply tacrolimus under occlusion overnight to the affected areas but she did not consent to this treatment.

ACKNOWLEDGEMENTS

The authors thank Hannelore Bischof, Birgit Fehrenbacher, Helga Möller and Renate Nordin (Department of Dermatology, University of Tübingen, Germany) for excellent technical assistance, and Professor Dr W. Burgdorf (Department of Dermatology and Allergology, University of Munich) for critical reading of the manuscript.

REFERENCES


Acta Derm Venereol 86